Company announcement – No. 42 / 2024

Follow this link:
Total number of shares and voting rights in Zealand Pharma on August 30, 2024

- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications- No new safety signals observed at interim analysis- Primary endpoint of progression free survival projected to be reached in the first half of 2025

Continue reading here:
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with...

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Go here to see the original:
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update

August 30, 2024

Read the rest here:
Receipt of Nasdaq Delisting Determination - Plans to Appeal

George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024

More here:
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC...

Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients Proceeds to be used for development of lead compound tuspetinib in combination therapy as frontline treatment for newly diagnosed AML patients

Read the original:
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop...

SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant.

Link:
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer

SHANGHAI, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2024 interim financial results and provided corporate updates.

The rest is here:
Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates

Tokyo, Japan and Cambridge, UK, 2 September 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – announces that it will receive a US$35 million payment from Neurocrine Biosciences (‘Neurocrine’), triggered by the successful completion of the Phase 2 trial with NBI-1117568 (NBI-‘568) in adults with schizophrenia, as announced on 28 August 2024. Receipt of the US$35 million payment will be recognized as one-time revenue in the third quarter of 2024.

Visit link:
Nxera Pharma to Receive US$35 Million from Neurocrine Biosciences upon Positive Phase 2 Data for Partnered Schizophrenia Candidate NBI-1117568

Oslo, 2 September 2024 - PCI Biotech (OSE: PCIB), today announce that the Board of Directors has granted share options to key employees.

Originally posted here:
PCI Biotech: Employee share option scheme

Go here to read the rest:
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in...

Oxford UK September 2nd, 2024. Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic viral therapies, has been awarded £2M from Innovate UK’s prestigious Transforming Cancer Therapeutics grant funding competition to support the clinical development of its lead candidate THEO-260. This non-dilutive funding adds to the £19M raised earlier this year from a strong investor syndicate comprising M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and Oxford University Innovation.

Read more:
Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

Follow this link:
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today

CLEVELAND, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the original:
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ad hoc announcement pursuant to Art. 53 LR

See more here:
Amended terms of Idorsia’s 2024 convertible bonds become effective

BOSTON, Mass., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will share the topline results from the Phase 2 EMBOLD study of relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies (DEEs) on Tuesday, September 3, 2024, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the trial results.

See original here:
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and...

SAN CARLOS, Calif., Sept. 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, September 3, 2024, at 8:00 a.m. Eastern Time to present topline results from the Phase 1/2 study evaluating the safety, tolerability and immunogenicity of VAX-31, the Company’s 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy adults aged 50 and older.

View original post here:
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine...

Clermont-Ferrand (France), 3 September 2024 (06:45 CET). CARBIOS, (Euronext Growth Paris: ALCRB), a pioneer in the development and industrialization of biological technologies to reinvent the life cycle of plastic and textiles, announces the appointment of Tommy Maussin as its Chief Marketing Officer, effective 2 September 2024.  His mission involves developing and overseeing CARBIOS’ global marketing and sales activities with brands across various industries, including packaging, textiles, luxury, automotive, cosmetics, healthcare, and industrial goods. Tommy will be responsible for enhancing CARBIOS’ global presence to initiate and conclude commercial agreements with brand owners. His proven track record of profitable businesses in a variety of industries, and in complex and international environments, is expected to play a pivotal role in shaping CARBIOS’ customer-centric marketing strategies moving forward. Tommy Maussin joins the Executive Committee and reports to Emmanuel Ladent, Chief Executive Officer of CARBIOS.

Read the original:
CARBIOS appoints Tommy Maussin as Chief Marketing Officer and Executive Committee member to develop CARBIOS’ presence with brands worldwide

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION INTO OR IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN, SOUTH AFRICA OR ANY OTHER STATE OR JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. NOT FOR DISTRIBUTION TO ANY U.S. PERSON. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS PRESS RELEASE.

More:
QIAGEN N.V. launches non-US offering of net share settled convertible bonds

Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season. There are currently no approved human vaccines for Lyme disease, and VLA15 is the Lyme disease vaccine candidate which has advanced the furthest along the clinical development timeline, with two Phase 3 trials in progress. The Centers for Disease Control and Prevention (CDC) has estimated that approximately 476,000 people in the U.S. are diagnosed and treated for Lyme disease each year and 129,000 cases are reported annually in Europe.1,2

Follow this link:
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate